What Is the Role of the Placebo Effect for Pain Relief in Neurorehabilitation? Clinical Implications From the Italian Consensus Conference on Pain in Neurorehabilitation by Castelnuovo, Gianluca (ORCID:0000-0003-2633-9822) et al.
May 2018 | Volume 9 | Article 3101
Review
published: 18 May 2018
doi: 10.3389/fneur.2018.00310
Frontiers in Neurology | www.frontiersin.org
Edited by: 
Marco Sarà, 
San Raffaele Cassino, Italy
Reviewed by: 
Sergio Bagnato, 
Fondazione Istituto G. Giglio di 
Cefalù, Italy  
Raffaele Palmirotta, 
Università degli studi di 
Bari Aldo Moro, Italy
*Correspondence:
Gianluca Castelnuovo 
gianluca.castelnuovo@unicatt.it
Specialty section: 
This article was submitted 
to Neurotrauma, 
a section of the journal 
Frontiers in Neurology
Received: 15 January 2018
Accepted: 19 April 2018
Published: 18 May 2018
Citation: 
Castelnuovo G, Giusti EM, 
Manzoni GM, Saviola D, Gabrielli S, 
Lacerenza M, Pietrabissa G, 
Cattivelli R, Spatola CAM, Rossi A, 
Varallo G, Novelli M, Villa V, Luzzati F, 
Cottini A, Lai C, Volpato E, 
Cavalera C, Pagnini F, Tesio V, 
Castelli L, Tavola M, Torta R, 
Arreghini M, Zanini L, Brunani A, 
Seitanidis I, Ventura G, Capodaglio P, 
D’Aniello GE, Scarpina F, Brioschi A, 
Bigoni M, Priano L, Mauro A, Riva G, 
Di Lernia D, Repetto C, Regalia C, 
Molinari E, Notaro P, Paolucci S, 
Sandrini G, Simpson S, 
Wiederhold BK, Gaudio S, 
Jackson JB, Tamburin S and 
Benedetti F (2018) What Is the Role 
of the Placebo Effect for Pain Relief in 
Neurorehabilitation? Clinical 
Implications From the Italian 
Consensus Conference on Pain 
in Neurorehabilitation. 
Front. Neurol. 9:310. 
doi: 10.3389/fneur.2018.00310
what is the Role of the Placebo 
effect for Pain Relief in 
Neurorehabilitation? Clinical 
implications From the italian 
Consensus Conference on Pain  
in Neurorehabilitation
Gianluca Castelnuovo1,2*, Emanuele Maria Giusti1,2, Gian Mauro Manzoni1,3,  
Donatella Saviola4, Samantha Gabrielli 5, Marco Lacerenza5, Giada Pietrabissa1,2,  
Roberto Cattivelli 1,2, Chiara Anna Maria Spatola1,2, Alessandro Rossi1, Giorgia Varallo1, 
Margherita Novelli 1, Valentina Villa1, Francesca Luzzati 6, Andrea Cottini6, Carlo Lai7, 
Eleonora Volpato2,8, Cesare Cavalera2, Francesco Pagnini2,9, Valentina Tesio10,  
Lorys Castelli 10, Mario Tavola11, Riccardo Torta12, Marco Arreghini13, Loredana Zanini13, 
Amelia Brunani13, Ionathan Seitanidis13, Giuseppe Ventura13, Paolo Capodaglio13,  
Guido Edoardo D’Aniello1,2, Federica Scarpina1, Andrea Brioschi14, Matteo Bigoni14, 
Lorenzo Priano12,14, Alessandro Mauro12,14, Giuseppe Riva1,2, Daniele Di Lernia2,  
Claudia Repetto2, Camillo Regalia2, Enrico Molinari1,2, Paolo Notaro15, Stefano Paolucci16, 
Giorgio Sandrini17,18, Susan Simpson19,20, Brenda Kay Wiederhold21, Santino Gaudio22, 
Jeffrey B. Jackson23, Stefano Tamburin24 and Fabrizio Benedetti12 On Behalf of the Italian 
Consensus Conference on Pain in Neurorehabilitation
1 Istituto Auxologico Italiano IRCCS, Psychology Research Laboratory, San Giuseppe Hospital, Verbania, Italy, 2 Department 
of Psychology, Catholic University of Milan, Milan, Italy, 3 Faculty of Psychology, eCampus University, Novedrate, Italy, 
4 Cardinal Ferrari Rehabilitation Center, Santo Stefano Rehabilitation Istitute, Fontanellato, Italy, 5 Pain Medicine Center,  
San Pio X Clinic, Humanitas, Milan, Italy, 6 IRCCS Galeazzi Orthopedic Institute, Milan, Italy, 7 Department of Dynamic and 
Clinical Psychology, Sapienza University of Rome, Rome, Italy, 8 HD Respiratory Rehabilitation Unit, IRCCS Fondazione Don 
Carlo Gnocchi, Milan, Italy, 9 Department of Psychology, Harvard University, Cambridge, MA, United States, 10 Department of 
Psychology, University of Turin, Turin, Italy, 11 Anesthesia and Intensive Care, ASST Lecco, Lecco, Italy, 12 Department of 
Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy, 13 Istituto Auxologico Italiano IRCCS, Rehabilitation  
Unit, San Giuseppe Hospital, Verbania, Italy, 14 Istituto Auxologico Italiano IRCCS, Department of Neurology and 
Neurorehabilitation, San Giuseppe Hospital, Verbania, Italy, 15 Pain Medicine, Anesthesiology Department, A.O. Ospedale 
Niguarda ca Granda, Milan, Italy, 16 Fondazione Santa Lucia IRCCS, Rome, Italy, 17 C. Mondino National Neurological Institute, 
Pavia, Italy, 18 Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy, 19 University of South Australia, 
Adelaide, SA, Australia, 20 Regional Eating Disorders Unit, NHS Lothian, Livingston, United Kingdom, 21 Virtual Reality Medical 
Institute, Brussels, Belgium, 22 Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, 
Sweden, 23 Virginia Tech, Falls Church, VA, United States, 24 Department of Neurosciences, Biomedicine and Movement 
Sciences, University of Verona, Verona, Italy
Background: It is increasingly acknowledged that the outcomes of medical treatments 
are influenced by the context of the clinical encounter through the mechanisms of the 
placebo effect. The phenomenon of placebo analgesia might be exploited to maximize 
the efficacy of neurorehabilitation treatments. Since its intensity varies across neurolog-
ical disorders, the Italian Consensus Conference on Pain in Neurorehabilitation (ICCP) 
summarized the studies on this field to provide guidance on its use.
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Methods: A review of the existing reviews and meta-analyses was performed to assess 
the magnitude of the placebo effect in disorders that may undergo neurorehabilitation 
treatment. The search was performed on Pubmed using placebo, pain, and the names 
of neurological disorders as keywords. Methodological quality was assessed using a 
pre-existing checklist. Data about the magnitude of the placebo effect were extracted 
from the included reviews and were commented in a narrative form.
Results: 11 articles were included in this review. Placebo treatments showed weak 
effects in central neuropathic pain (pain reduction from 0.44 to 0.66 on a 0–10 scale) 
and moderate effects in postherpetic neuralgia (1.16), in diabetic peripheral neuropathy 
(1.45), and in pain associated to HIV (1.82). Moderate effects were also found on pain 
due to fibromyalgia and migraine; only weak short-term effects were found in complex 
regional pain syndrome. Confounding variables might have influenced these results.
Clinical implications: These estimates should be interpreted with caution, but under-
score that the placebo effect can be exploited in neurorehabilitation programs. It is not 
necessary to conceal its use from the patient. Knowledge of placebo mechanisms can 
be used to shape the doctor–patient relationship, to reduce the use of analgesic drugs 
and to train the patient to become an active agent of the therapy.
Keywords: neurorehabilitation, placebo, pain, clinical psychology, health psychology, placebo effect, consensus 
conference
iNTRODUCTiON
The placebo effect can be defined as the improvement in the patient’s 
symptoms after the administration of an inert substance in a context 
inducing positive expectations about its effects (1, 2). This phenom-
enon is raising a growing interest in the field of pain management 
in patients with neurological disorders. Neurorehabilitation treat-
ments could be delayed or hampered by pain symptoms, whose 
management could be particularly difficult since the available 
treatments may provide only a moderate relief at the cost of various 
undesirable side effects (3–5). In this context, knowledge of the 
mechanisms of the placebo effect could be important. Rather than 
representing an alternative treatment modality, this phenomenon 
can be exploited to enhance the effectiveness of the care (6).
In the last decades, research has shifted its focus from the 
inert substance to the psychosocial context surrounding its 
administration. The placebo response can be considered as a form 
of contextual healing, since the beneficial outcome is due to the 
context of the clinical encounter, rather than to a specific efficacy 
of the actual treatment (7–9). This complex phenomenon can be 
described as the emerging effect of the doctor–patient relationship 
and of the psychosocial context in which it takes place (10). The 
patient’s memory of previous treatments, personal characteristics, 
and expectations modulate and are modulated by the interaction 
with the doctor, whose characteristics and expectations, in turn, 
influence the context of the encounter. Therefore, the therapeutic 
ritual itself is the trigger of the placebo effect (11).
The placebo effect is grounded in physiological mechanisms. 
Different processes can be involved, depending both on the 
physical or psychological state of the patient and on the context. 
Various theoretical frameworks have been proposed to under-
stand them, each focusing on a different set of variables, such as 
conditioning processes, patient expectations, individual attribu-
tions, and contextual factors (2, 12). Each of these processes was 
found to involve different neurobiological mechanisms, includ-
ing opioid, endocannabinoid, or dopamine ones (13–20). The 
presence of various mechanisms seems to reflect the complexity 
of the phenomenon, as well as the variety of neurobiological, 
psychological, and psychosocial processes involved.
The placebo effect varies across individuals and disorders. 
Studies are increasingly shedding some light on the individual 
differences, focusing on the role of genetics (21–23), on differ-
ences in the activation of the reward system (16), on differences 
in expectancy mechanisms and in the emotional appraisal of 
situations (24), or on the role of psychological variables. Among 
them, preliminary data corroborate the role of dispositional 
optimism and state anxiety (25–27), various personality traits 
(28, 29), hypnotizability and suggestibility (30, 31), reappraisal 
ability (32), beliefs (33), learning mechanisms (34), and traits 
linked to dopaminergic mechanisms such as novelty seeking (35).
On the other hand, differences across disorders have received 
less attention, especially in the field of neurorehabilitation. To 
exploit the analgesic potential of placebo treatments in this field, 
knowledge about its differential effects is required. On behalf of 
The Italian Consensus Conference on Pain in Neurorehabilitation 
(ICCPN), a multidisciplinary board aimed at developing the 
national guidelines on the assessment and treatment of pain in 
neurorehabilitation, our working group was established to sum-
marize the available studies on this topic.
MeTHODS
A review of the existing reviews and meta-analyses examining 
the role of the placebo effect in disorders that may undergo 
TaBle 1 | Critical Appraisal Checklist for Systematic Reviews.
1 Is the review question clearly and explicitly stated?
2 Were the inclusion criteria appropriate for the review question?
3 Was the search strategy appropriate?
4 Were the sources and resources used to search for studies adequate?
5 Were the criteria for appraising studies appropriate?
6 Was critical appraisal conducted by two or more reviewers independently?
7 Were the methods used to combine studies appropriate?
8 Was the likelihood of publication bias assessed?
9 Were recommendations for policy and/or practice supported by the  
reported data?
10 Were the specific directives for new research appropriate?
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neurorehabilitation treatment was performed. This research 
design was chosen since (a) it allowed to summarize a high 
amount of studies on such a broad topic and (b) literature reviews 
focusing on each disorder were already present. Both systematic 
and non-systematic reviews were considered for inclusion since it 
was hypothesized that the quality of the existing literature about 
each disorder would be heterogeneous. Studies were, therefore, 
included if they reported reviews, with or without meta-analysis, 
presenting data about the effects of a placebo treatment on pain 
intensity in disorders that may undergo neurorehabilitation treat-
ment. Only articles written in English language were considered. 
Studies were excluded if they did not report summary data about 
the effects of placebo treatments.
An initial search was performed on July 2014, imposing no 
restraints on the articles’ publication date. Subsequently, a research 
update took place on March 2017, restraining the search to 
articles published from 2014 to 2017. Both the searches were 
performed on PubMed using the following keywords: “placebo” 
(research restricted to the title) “nervous system disease” (as a 
MeSH word), the names of the primary neurological disorders 
and “pain.” The inclusion and exclusion criteria were used by one 
of the authors to judge the eligibility of the studies based on the 
articles’ titles, abstracts and, finally, full texts. The bibliographies 
of the selected articles were analyzed to identify other potentially 
relevant reviews. The methodological quality of included stud-
ies was then assessed using the Critical Appraisal Checklist for 
Systematic Reviews (Table 1) (36). When assessing the methodo-
logical quality of non-systematic reviews, items from 5 to 8 of this 
checklist were not considered.
The following data were extracted from the included reviews: 
study design of the review, disorder addressed by the review, par-
ticipants’ details, study design of the included studies, number of 
electronic databases accessed during the search, date range of the 
search, number of studies included, number of subjects included 
in placebo arms, total number of subjects, instruments used by 
the studies to assess pain intensity, and quantitative results. Since 
the aim of the present review was not to assess if placebo treat-
ments are evidence-based interventions, the quality of evidence 
was not graded and no recommendations were made. Instead, 
the results of the reviews were synthesized in a narrative form. 
Results from excluded reviews or from primary studies that were 
found during the search that were considered relevant to give 
insight to areas not explored by the included reviews were also 
commented.
ReSUlTS
Overall, the searches yielded 872 records. From this sample, 11 
reviews were included in the present review. The flowchart of the 
study search and selection is reported in Figure 1.
Among the included reviews, 10 out of 11 were systematic 
and 9 included a meta-analysis. Five of these reviews focused on 
peripheral and/or central neuropathic pain disorders, three on 
migraine and the remaining on chronic regional pain syndrome, 
fibromyalgia, or mixed chronic pain conditions. The characteris-
tics of the studies are reported in Table 2.
The methodological quality of the included reviews was 
variable (Table 3). Among the systematic reviews, three studies 
did not meet at least six items of the critical appraisal checklist 
(39, 40, 44), but none of them showed substantial biases that 
may hinder the interpretation of their results.
PlaCeBO eFFeCT iN PaiN CONDiTiONS 
iN NeUROReHaBiliTaTiON
The main quantitative results of the included reviews generally 
show that the placebo effect has a low to moderate effect on pain 
across the various disorders (Table 4). However, differences are 
visible, especially when neuropathic and non-neuropathic pain 
disorders are contrasted.
Various reviews and meta-analyses addressed the role of pla-
cebo in neuropathic pain disorders and found a noticeable hetero-
geneity between peripheral and central ones (43–46). In general, 
the placebo effect was found to be more intense in the former 
than in the latter. A meta-analytic study estimated the intensity 
of the placebo effect in various neuropathic pain disorders, and 
explored both the average pain reduction and the percentage of 
patients who positively responded to the placebo treatment (44). 
On a 0–10 scale, the average decrease in pain severity was 1.82 
in pain associated with HIV (percentage of positive responders: 
48.2%), 1.45 in painful diabetic peripheral neuropathy (percent-
age of positive responders: 20%), 1.16 in postherpetic neuralgia 
(percentage of positive responders: 11.5%), and between 0.44 
and 0.64 in central neuropathic pain (percentage of positive 
responders: 7.2%) (42, 44). Other studies confirmed that, among 
the disorders associated with peripheral neuropathic pain, the 
placebo effect was higher in painful diabetic peripheral neuropa-
thy than in postherpetic neuralgia (43). In contrast, the placebo 
effect in complex regional pain syndrome, a disorder with some 
neuropathic characteristics (48), seems to be nearly absent, with 
only weak short-term effects (37). In neuropathic pain disorders, 
the intensity of the placebo effect is modulated by the duration 
of treatment, with longer treatments associated with increased 
effects, and by the duration and intensity of initial pain, with 
longer duration of and higher intensity associated with a reduced 
placebo response (42, 43, 45).
The intensity of the placebo effect is generally higher in non-
neuropathic pain disorders. A meta-analysis by Madsen et  al. 
(47) compared the effects of acupuncture, placebo acupuncture, 
and a no-treatment condition on pain from various disorders, 
including headache (tension type, migraine), nociceptive pain 
(osteoarthritis, low back pain), iatrogenic pain (postoperative, 
FigURe 1 | Flowchart of the records search and selection.
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procedural pain during colonoscopy, abdominal scar pain), 
and fibromyalgia. In this study, acupuncture was found to have 
slightly stronger effects (i.e., 0.4 points on a 0–10 scale) than pla-
cebo acupuncture, whereas a moderate difference (i.e., 1.0 points) 
was found between placebo acupuncture and no acupuncture 
conditions.
Hauser et  al. (38) studied both the placebo and the nocebo 
effect in the management of fibromyalgia, and estimated that the 
percentage of patients experiencing a 50% pain reduction after 
a placebo treatment was 18.6% and that the dropout rate due to 
adverse events was 10.9%. In contrast, groups receiving a true 
drug showed a higher rate of responders (31.6%) and a higher 
dropout rate due to adverse events (20.4%). This study did not 
compare the improvement in the placebo group with that in the 
untreated groups.
Despite the variability of their effects, placebo treatments 
were found to be associated with both short- and long-term 
improvements in migraine sufferers (39, 41). Placebo groups 
showed an improvement of pain symptoms in 26% of cases, 
and 21% of patients taking placebo for migraine prophylaxis 
improved. For both outcomes, the efficacy of the placebo 
treatment was estimated to be half of that of active drugs. 
The placebo treatment type influenced its efficacy, with sham 
acupuncture and sham surgery being more effective than oral 
placebos (41). These effects were accompanied by a high rate 
of adverse events (39–41). The presence of adverse events in 
case of placebo administration is in line with the nature of 
placebo, since their characteristics are generally similar to the 
characteristics of the active drugs against which placebo is 
compared (49).
The size of the placebo effect and its variability across dis-
orders and type of placebo treatment is apparent also when 
non-neurological disorders are considered. It was estimated 
that placebo treatments for osteoarthritis resulted in an overall 
moderate effect (effect size = 0.51) and that topical and intra-
articular placebos are more effective than oral ones (effect 
size differences of 0.20 and 0.29, respectively) (50, 51). Other 
estimates show that the size of the placebo effect is equivalent to 
72% of that of the drug treatment in burning mouth syndrome 
(52) and that it leads to pain remission rates of 19.9% in chronic 
pancreatitis (53).
iMPliCaTiONS FOR CliNiCal PRaCTiCe
The effectiveness of placebo treatments should not be overesti-
mated. Most of the studies on this topic showed high heterogene-
ity and did not take into account confounding variables, such 
as spontaneous remission of symptoms or regression toward 
the mean, thus potentially overestimating the intensity of the 
placebo response. In addition, various authors underlined that 
(a) placebo effect is higher when subjective rather than objective 
outcome measures are explored (54); (b) bias may be present in 
patients’ responses (54); (c) each individual responds differently 
to placebos (55, 56), and (d) outcomes vary consistently across 
studies and methodological design (57). These limitations are 
prominent in studies on placebo treatments, and may impede 
TaBle 2 | Description of the included reviews.
Reference Type of review Disorder Participants details Study design of the 
included studies
Number of 
databases 
searched
Date range of 
the database 
search
Number of 
trials included
Number of 
subjects in 
placebo arms
Total  
number of 
subjects
Mbizvo et al. (37) Meta-analysis Complex 
regional pain 
Syndrome
Patients with complex regional pain 
syndrome I and II
RCT and controlled 
studies
5 (+ other 
sources)
1966–2013 20 (18 
included in the 
meta-analysis)
340 Not reported
Hauser et al. (38) Meta-analysis Fibromyalgia Patients with fibromyalgia, both males and 
females
Double-blind RCT 3 up to 2012 18 3,546 6,589
Loder et al. (39) Meta-analysis Migraine Acute migraine sufferers RCT and controlled trials 1 1991–2002 31 Not reported Not reported
Macedo et al. (40) Meta-analysis Migraine Migraine sufferers Double-blind RCT 1 1998–2004 32 (22 
included in the 
meta-analysis)
1,416 4,519
Meissner et al. (41) Meta-analysis Migraine Migraine sufferers RCT 4 up to 2012 102 (79 
included in the 
meta-analysis)
Not reported 9,287
Cragg et al. (42) Meta-analysis Neuropathic 
pain (central)
Patients with spinal cord injury, stroke or 
multiple sclerosis
Placebo-controlled trials 1 up to 2015 39 1,153 Not reported
Arakawa et al. (43) Meta-analysis Neuropathic 
pain
Patients with peripheral or central 
neuropathic pain
Placebo-controlled trials 3 1995–2014 71 Not reported 6,126
Cepeda et al. (44) Meta-analysis Neuropathic 
pain
Diabetic neuropathy, postherpetic neuralgia, 
central neuropathic pain, HIV-associated 
neuropathic pain
RCT 1 (+ other 
sources)
1995–2009 141 Not reported 6,239
Quessy and 
Rowbotham (45)
Topical review Neuropathic 
pain
Patients with painful diabetic neuropathy or 
postherpetic neuralgia
RCT Not reported Not reported 35 3,355 Not reported
Tuttle et al. (46) Systematic 
review
Neuropathic 
pain
Patients with various types of neuropathic 
pain
Double-blind RCT 3 1980–2013 84 Not reported Not reported
Madsen et al. (47) Meta-analysis Chronic pain Patients with headache, migraine, 
osteoarthritis, low back pain, postoperative 
pain, colonoscopy, fibromyalgia or scar pain
3-armed RCT 5 up to 2008 13 943 3,025
RCT, randomized controlled trials.
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TaBle 3 | Quality assessment of the included reviews.
Reference item 1 item2 item 3 item 4 item 5 item 6 item 7 item 8 item 9 item 10
Mbizvo et al. (37) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Hauser et al. (38) ✓ ✓ ✓ ✓ ⨯ ⨯ ✓ ⨯ ✓ ✓
Loder et al. (39) ✓ ⨯ ⨯ ⨯ ✓ ⨯ ✓ ⨯ ✓ ⨯
Macedo et al. (40) ✓ ✓ ✓ ⨯ ⨯ ⨯ ✓ ⨯ ⨯ ⨯
Meissner et al. (41) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ⨯ ✓ ✓
Cragg et al. (42) ✓ ✓ ✓ ⨯ ⨯ ⨯ ✓ ✓ ✓ ✓
Arakawa et al. (43) ✓ ✓ ✓ ✓ ⨯ ⨯ ✓ ⨯ ✓ ✓
Cepeda et al. (44) ✓ ✓ ✓ ⨯ ⨯ ⨯ ✓ ⨯ ✓ ⨯
Quessy and Rowbotham (45) ⨯ ✓ ⨯ ⨯ n\a n\a n\a n\a ✓ ⨯
Tuttle et al. (46) ✓ ✓ ✓ ✓ ⨯ ⨯ ✓ ✓ ✓ ✓
Madsen et al. (47) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ⨯ ✓ ✓
6
Castelnuovo et al. Placebo in Neurorehabilitation
Frontiers in Neurology | www.frontiersin.org May 2018 | Volume 9 | Article 310
TaBle 4 | Quantitative findings of the included reviews.
Reference Disorder instruments or outcome 
data
Results Comments
Mbizvo  
et al. (37)
Complex 
Regional Pain 
Syndrome
VAS, NRS (if other scales were 
used, scores were converted)
Mean change in 0–100 VAS or NRS at 15–30 min 
posttreatment: 18,423, 95% CI [−33.15, −3.65]
Mean change in 0–100 VAS or NRS at 1 week 
posttreatment: −6,772, 95% CI [−14.92, 1.38]
Mean change in 0–100 VAS or NRS at 3–4 weeks 
posttreatment: 0.326, 95% CI [−2.329, 2.981]
Mean change in 0–100 VAS or NRS at 6 weeks 
posttreatment: −3.87, 95% CI [−9.48, 1.71]
Only mean change at 15–30 min 
posttreatment was significant. Study 
design and invasiveness of the placebo 
treatment affected placebo response
Hauser  
et al. (38)
Fibromyalgia 0–10 or 0–100 VAS or NRS Percentage of patients with a 50% reduction of pain 
intensity in placebo arms: 18.6%, 95% CI [17.4–19.9] vs 
31.6%, 95% CI [30.5, 32.7] of patients in active drugs 
arms
Nocebo effect: dropout due to adverse 
events: 10.9%, 95% CI [9.9–11.9]. 
Confounders: percentage of women or 
Caucasians included and study duration 
are positively correlated with placebo 
effect, number of continents is negatively 
associated with placebo effect
Loder  
et al. (39)
Migraine Percentage of pain-free 
patients, response rate, 
adverse events rate
Percentage of pain-free patients at two hours: 6.08% 
(±4.83)
Response rate at 2 h: 28.90% (±8.55)
Adverse events rate at 2 h: 23.4% (±14.05)
Migraine prophylaxis: percentage of 
pain-free patients: 6.02%; response rate: 
25.52%; adverse events rate: 19.56%
Macedo  
et al. (40)
Migraine Percentage of improved 
patients, attacks per month 
reduction, adverse events rate
Migraine prophylaxis: percentage of improved patients: 
21%, 95% CI [13%, 28%]
Attacks per month reduction: −0.8, 95% CI [0.4, 1.1]
Adverse events rate: 30%, 95% CI [17%, 43%]
Significant confounders: study design 
and country
Meissner  
et al. (41)
Migraine Proportion of responders 
(directly extracted or calculated 
from: number of days with 
migraine, number of days with 
headache, or 50% decrease in 
headache scales scores)
Proportion of placebo responders at 3–4 months: 0.26, 
95% CI [0.22, 0.30] vs responders to active treatments: 
0.42, 95% CI [0.38, 0.45]
Difference between placebo treatments: sham surgery: 
0.58, 95% CI [0.37, 0.77]; sham acupuncture: 0.38, 95% 
CI [0.30, 0.47]; oral placebo: 0.22, 95% CI [0.17, 0.28]
Subgroup analysis: when all confounders 
are considered, blinding of subjects and 
type of placebo treatment is positively 
correlated with placebo magnitude
Cragg  
et al. (42)
Neuropathic 
pain (central)
VAS, NRS Overall mean change in pain rating (0–10): −0.64 95% CI 
[−0.83, −0.45]
Meta-regression: weaker placebo effect 
associated with higher chronic pain 
duration, baseline pain variability, cross-
over study design. High heterogeneity
Arakawa  
et al. (43)
Neuropathic 
pain
VAS, NRS Neuropathic pain (both central and peripheral): percentage 
of patients with 50% pain intensity reduction: 23%, 95% 
CI [20%, 25%], percentage of patients with 30% pain 
intensity reduction: 37%, 95% CI [34%, 41%]
Among the results of the multivariable 
analysis, baseline pain intensity was 
found to be negatively correlated with 
placebo response in postherpetic 
neuralgia and in painful diabetic 
peripheral neuropathy
Peripheral neuropathic pain: percentage of patients with 
50% pain intensity reduction: 23%, 95% CI [21, 26], 
percentage of patients with 30% pain intensity reduction: 
39%, 95% CI [34%, 42%]
(Continued )
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to predict their effects in routine clinical practice. It is recom-
mended to take these treatments into consideration in neurore-
habilitation settings only after traditional ones have failed or are 
contraindicated (58–64).
Rather than simply representing an alternative type of treat-
ment, the placebo effect is a phenomenon that can increase 
the effectiveness of the care, since it constitutes the process 
through which the doctor–patient relationship becomes 
therapeutic. The knowledge of relevance of the placebo effect 
for each specific pain disorder is recommended to exploit its 
potential. For example, placebo response is generally small in 
central neuropathic pain, where pharmacological and non-
pharmacological treatments have also limited efficacy, while 
it appears to represent half of the effect of active treatments 
in the prophylaxis of primary headaches. This information is 
central to shape the communication with the patient, allowing 
to provide a trustworthy explanation of the positive effects of 
the therapeutic context.
It is increasingly acknowledged that concealment is not 
necessary for the placebo effect to take place. Research on 
open-label placebos treatments, i.e., non-deceptive treatments 
in which the participants are alerted that the therapeutic mean 
is inert, but are informed about the effects of the administration 
of placebos, corroborates this claim. Further studies are needed, 
Reference Disorder instruments or outcome 
data
Results Comments
Central neuropathic pain: percentage of patients with 50% 
pain intensity reduction: 14%, 95% CI [10, 19], percentage 
of patients with 30% pain intensity reduction: 26%, 95% 
CI [19%, 33%]
Cepeda  
et al. (44)
Neuropathic 
pain
Mean decrease in 0–10 pain 
intensity, responder rate 
(percentage of patients with 
50% pain intensity reduction)
Overall: 1.2 (±1.0) mean reduction in pain intensity, RR 
17% (range: 0–43%)
Diabetic neuropathy: 1.45, 95% CI [1.35–1.55] mean 
reduction in pain intensity, RR of 20.2%, 95% CI 
[14.6–25.8]
Postherpetic neuralgia: 1.16, 95% CI [1.03–1.29] mean 
reduction in pain intensity, RR of 11.5%, 95% CI [8.4–14.5]
Central neuropathic pain 0.53, 95% CI [0.19–0.86] mean 
reduction in pain intensity, RR of 7.2%, 95% CI [2.1–12.3]
HIV-associated neuropathic pain: 1.82, 95% CI [1.51–
2.12], RR of 42.8%, 95% CI [34.9–50.7]
Trials evaluating NMDA blockers 
showed weaker placebo response, age 
was positively correlated with placebo 
response
Quessy and 
Rowbotham 
(45)
Neuropathic 
pain
VAS, NRS Median change in pain intensity in PDN: 26% (range 
11–35%); in PHN 15–16 (range 4–44%)
The placebo response was found to vary 
throughout the time course of trials and 
to be influenced by trial duration
Tuttle  
et al. (46)
Neuropathic 
pain
VAS, NRS Mean change in pain intensity: 18.3%, 95% CI  
[15.2%, 21.4%]
Multivariable analysis: placebo 
magnitude is positively correlated with 
sample size; in studies performed in the 
US the placebo magnitude is positively 
correlated with study duration
Madsen  
et al. (47)
Various types 
of pain
SMD based on WOMAC, VAS 
or Likert-type rating scales
Acupuncture vs placebo SMD: −0.17, 95% CI [−0.26, 
−0.08]; placebo vs nontreated controls SMD: −0.42,  
95% CI [−0.60, −0.23]
High heterogeneity
VAS, Visual Analogue Scale; NRS, Numeric Rating Scale; MPQ, McGill Pain Questionnaire; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index Pain Score; CI, 
Confidence Interval; SMD, standardized mean difference; RR, responders rate.
TaBle 4 | Continued
but open-label placebo treatments seem to have a similar or 
even higher efficacy than deceptive ones and are associated with 
marked improvement of symptoms of a variety of conditions 
(65–70). These treatments are more easily accepted by patients 
(71) and overcome the ethical and legal implications of the 
deceitful prescription of placebos, which violates the principle 
of the informed consent and may affect the trust that shape the 
doctor–patient relationship (72, 73).
Various techniques can be used to improve the patient’s 
symptoms through placebo mechanisms. A possible strategy is 
to maximize the patient’s expectations regarding the treatment. 
This can be done by informing the patient on the nature and 
effects of placebo analgesia, by assessing the appropriateness 
of the patient’s beliefs about his disorder and its treatment and 
providing information in case they are excessively positive or 
negative. In this case, it would be important to balance the 
information regarding the positive and negative effects of the 
treatment, underlying the role of the positive ones despite its 
undesired effects, and by cognitively reinforcing the impact of 
the positive outcomes as they appear (74–76). Furthermore, 
it is possible to exploit conditioning mechanisms to support 
the pharmacological therapy. Once the person associates the 
characteristics of the analgesic agent, such as appearance and 
taste, to the reduction of pain, it could be possible to employ 
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inert substitutes with the same characteristics to obtain similar 
results (6). Using similar methods, it would be possible, after 
an adequate initial conditioning, to progressively reduce the 
administration of medication by alternatively switching to a 
placebo with similar characteristics (74, 77). Finally, the patient 
can also be trained to create those conditions that maximize the 
placebo effect, for example by focusing on the characteristics 
of the analgesic agent or by increasing his own expectations 
through appropriate information (75).
It should be underscored that all these techniques need to take 
place within the context of a doctor–patient relationship. The 
relational aspect of the placebo effect resides in the person’s feel-
ing of being taken care for and in the process by which he himself 
becomes an active agent of the therapy (78). Having an empathic 
attitude, reassuring the patient, helping him to self-manage his 
symptoms, emphasizing the role of interpersonal resources and 
creating therapeutic rituals during therapy represent key aspects 
of the relationship.
In conclusion, the neurorehabilitation team needs to address 
a variety of disorders, each of which responds differently to the 
placebo effect. It is, therefore, necessary to personalize all these 
features depending on the disorder and on the patient’s charac-
teristics. Studies are beginning to clarify the genetic, biological, 
psychological, and contextual factors that may enable to identify 
subjects with high or low likelihood of experiencing a placebo 
response (22, 28). To exploit the placebo effect, the doctor should 
collect information regarding not only about the patient’s disor-
der, but also about his personal characteristics and his context 
(74). The context of the doctor–patient relationship should be 
shaped so that the doctor does not focus only on the treatment of 
pain as a symptom of the neurological disorder, but is able to take 
care of the person as a whole.
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